Register for our free email digests:
Juniper Pharmaceuticals
http://www.juniperpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Juniper Pharmaceuticals
Pipeline Review: Large Potential Overactive Bladder Population Beckons
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.
Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Services
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.
- Juniper Pharma Services